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ABSTRACT
The marine environment constitutes an extraordinary resource for the discovery 
of new therapeutic agents. In the present manuscript we studied the effect of 3 
different sponge derived guanidine alkaloids, crambescidine-816, -830, and -800. 
We show that these compounds strongly inhibit tumor cell proliferation by down-
regulating cyclin-dependent kinases 2/6 and cyclins D/A expression while up-
regulating the cell cyclin-dependent kinase inhibitors -2A, -2D and -1A. We also 
show that these guanidine compounds disrupt tumor cell adhesion and cytoskeletal 
integrity promoting the activation of the intrinsic apoptotic signaling, resulting in 
loss of mitochondrial membrane potential and concomitant caspase-3 cleavage and 
activation. The crambescidin 816 anti-tumor effect was fnally assayed in a zebrafish 
xenotransplantation model confirming its potent antitumor activity against colorectal 
carcinoma in vivo.
Considering these results crambescidins could represent promising natural 
anticancer agents and therapeutic tools.
INTRODUCTION
The increasing interest in screening for novel agents 
from marine organisms is supported by their ability to 
synthesize an arsenal of bioactive secondary metabolites 
with pharmacologically significant activities and unusual 
chemical structures, quite different from those produced 
by terrestrial ones [1]. Cytarabine (Ara-C) and eribulin 
mesylate are notable examples of antitumor agents 
originally extracted from sponges that have been approved 
as anticancer drugs and are already on the market. Many 
others have made it to different phases of clinical trials, as 
for example, LAF389 and KRN7000 [1, 2]. Accordingly, 
sponges have emerged as an important target for research 
on new agents of therapeutic interest.
Crambe crambe is a marine encrusting sponge of 
the Poecilosclerida order from which several pentacyclic 
guanidine alkaloids (PGAs) have been isolated and 
structurally characterized since the first chemical studies 
were made in the early 90s [3, 4]. Nowadays these PGAs 
are divided into two families known as crambescins and 
crambescidins [3].
Crambescidins are a family of compounds very 
similar to the well-known marine alkaloid Ptilomycalin 
A, more specifically, they are pentacyclic guanidines 
linked by a linear ω-hydroxy fatty acid to a spermidine 
or hydroxispermidine unit (Figure 1A) [5]. Several of 
these molecules have been patented due to their cytotoxic, 
antifungal and antiviral activities and some of them, as for 
example crambescidin 816 (C816), also have recognized 
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effects over calcium ion channels [3, 5, 6]. Furthermore, 
in 2007 crambescidin 800 (C800) was also proposed as 
an antioxidant agent against hypoxia, nitric oxide and 
glutamate-induced oxidative stress [7]. Other previously 
reported biological activities of C800 include its ability 
to combat liver and blood stage of Plasmodium spp. [8] 
and to induce erythroid differentiation of chronic human 
myelogenous leukemia cells [9].
While some previous studies revealed the 
cytotoxicity of C816 against human colon carcinoma 
cells (IC50 0.24 μg/ml) [3] and others inquired the 
relationship between tumor selectivity and crambescidin 
alkaloids analogs structures [10], the understanding of 
the underlying cellular mechanisms responsible for their 
antitumor activities is scarce up to date. In this context, we 
previously assayed the transcriptomic alterations induced 
by C816 on the human liver carcinoma cell line HepG2 
showing that this compound arrests cell cycle progression 
disrupting cell-cell and cell-matrix adhesions [11].
Encouraged by these interesting findings we decided 
to further investigate C816 and other side chain analogs 
of the crambescidin family (C800 and C830) in order to 
elucidate the effects of each tested compound against a 
wide range of human-tumor-derived cell lines and their 
relative potency.
We also aim to determine whether these three 
PGAs might lead to tumor cell death through the same 
molecular pathways and to further characterize their 
mechanisms of action. For these purposes, crambescidins 
activities against cancer cells were assayed in vitro and 
C816 antitumor efficacy ultimately tested in vivo using a 
zebrafish xenograft model.
During the last decade the zebrafish (Danio rerio) 
has rapidly become a popular model organism in many 
areas of biomedical research since it presents several major 
advantages compared to rodents. The growing interest of 
both, adult and embryo stage zebrafish, in pharmacology 
is supported by several hallmarks of this small vertebrate 
as its fecundity, fast development, big offspring size, 
transparency, high genetic and physiological homology 
to humans and theease of genetic manipulation. These 
characteristics provide important utilities and opportunities 
to accelerate the process of drug discovery by contributing 
to disease modeling, assay of toxicity, bioavailability 
evaluation and lead molecules identification. Previous 
works have carefully evaluated the pros and cons of 
zebrafish cancer models and validated this approach [12–
14]. In fact, zebrafish xenografts have been widely used 
before as reliable whole-animal model systems to rapidly 
screen for small-molecule drug candidates [15–17].
RESULTS
Crambescidins reduce viability of tumor cells
C830 and C800 effects on tumor cell proliferation and 
survival were assayed by the MTT method. C816 (Figure 
1A) cytotoxicity against a wide range of tumor cells has 
been previously established (17). Based on these results, 
concentrations of 0.5 μM and 1 μM were selected in order to 
facilitate any possible comparison with existing data. Results 
showed that after 24 h just C830 decreased cell viability of 
lung non-small cancer cells (HOP-92) and colon carcinoma 
(HT-29) cells while, in the case of C800, no effect was 
observed (Figure 1B). Nevertheless, after 48 h either C830 
or C800 decreased tumor cells survival. C830 significantly 
decreased cell viability of all tested cell lines at the two 
concentrations assayed (Figure 1B). Cytotoxic activity of 
C800 was just significant against melanoma (SK-MEL-2) 
and ovarian carcinoma (OVCAR-3) cell lines (Figure 1B). 
Moreover, cell viability reduction caused by C830 was 
higher when compared with results obtained for C800 and 
lower when compared with those previously obtained for 
C816 (17). To quantify the effect produced by each of these 
compounds and to establish and compare their potency, IC50 
values against HepG2 cells were calculated.
The in vitro IC50 values of C816 and C830 after 48 
h of treatment were 0.57 μM and 9.73 μM, respectively 
(95% confidence intervals 0.41 μM-0.79 μM and 5.84 
μM-16.22 μM) (Figure 1C). Although at the same time-
point C800 significantly reduced tumor cell viability, the 
percentage of the maximum effect did not reach 50% 
(Figure 1C). Considering this, the IC50 after long-term 
treatments (72 h) was also determined for each of the three 
compounds. The IC50 values (95 % confidence limits) of 
C816, C830 and C800 were 0.18 μM (0.12 μM-0.25 μM), 
2.11 μM (1.48 μM-3.00 μM) and 2.66 μM (1.77 μM-4.13 
μM), respectively (Figure 1D).
Crambescidins 800 and 830 disrupt cellular 
adhesion and cytoskeletal integrity
Loss of cell attachment is one of the early effects 
of C816 on tumor cells. Alterations of focal adhesion 
plaques, tight junctions and cytoskeleton proteins start 
after short periods of exposure (6 h) to low concentrations 
(0.5 and 1 μM) of C816 and progress up to 24 h (17). 
To elucidate if cell detachment was just caused by C816 
or could be a broad effect of the crambescidin family of 
compounds, we assayed the effect of C830 and C800 on 
cell adhesion and cytoskeleton integrity. Considering the 
IC50values previously obtained, a concentration of 2.5 μM 
was selected in order to assure the adequate conditions to 
detect any possible alteration caused by these molecules. 
As a benchmark for comparison, treatments with 2.5 μM 
C816 were also included.
After 24 h both, C830 and C816, produced a 
remarkable occludin (OCLN) translocation from cell 
membrane to the cytoplasm. In the case of C800 a slight 
increase in occluding cytoplasmic levels was also observed 
(Figure 2A). Although all the crambescidins induced the 
internalization of OCLN from cell membrane, results 
showed that the translocation produced by C816 was higher 
when compared with that produced by C830 and C800. 
Oncotarget83073www.impactjournals.com/oncotarget
Figure 1: Crambescidins decrease viability of a wide range of tumor cells. A. Chemical structures of crambescidin 816, 
crambescidin 830 and crambescidin 800. B. Viability of HOP-92, OVCAR-3, HT-29, SK-MEL-2, OU-31 and MCF-7 cells after C830 
and C800 treatments for 24 and 48 h, determined by the MTT method. *Significant difference with respect to controls (p <0.01). C. Dose-
dependent decrease of cell viability in response to C816, C830 and C800 determined by the alamarBlue® assay. HepG2 cells were treated 
with different concentrations of C816, C830 and C800 ranging from 0.1 to 15 μM for 48 h to determine the IC50 dose. D. Dose-dependent 
decrease of HepG2 cells viability in response to 0.1-15 μM C816, C830 and C800 and IC50 determination at 72 h.
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Similarly, changes in OCLN localization produced by C830 
were more notable than the alterations caused by C800.
Crambescidins also reduced tumor cells adhesion by 
decreasing vinculin-containing adhesion plaques leading 
to reduction of cell-substratum interactions (Figure 2A). 
Cytoskeleton alterations induced by C816 and C830 
were due to tubulin depolymerization and disassembly 
of actin stress fibers (Figure 2A). Once again, observed 
effects were more apparent for C816 followed by C830 
and C800, respectively. Crambescidins effect on tubulin 
polymerization was also assayed. These compounds 
partially inhibited or delayed tubulin polymerization being 
C816 the most potent of the three PGAs (Supplementary 
Figure S2A, S2B).
Figure 2: Crambescidins alter cell adherence and cytoskeletal integrity of tumor cells. A. OCLN (green), VCL (red), 
F-ACTA (green) and β-TUBB (red) detection by confocal microscopy in control and 2.5 μM C816, C830 and C800-treated cells after 24 h. 
Colocalization of F-ACTA and VCL is shown in yellow and representative images of control and treated cells are shown. Hoechst 33258 
was included for nuclei counterstaining (blue). B. Left: Determination of soluble CLDN2, OCLN, TUBB, VLC and GADPH levels. HepG2 
cells were treated with 2.5 μM C816, C830 and C800 for 24 h and then soluble protein fractions obtained from cell lysates of treated and 
untreated cells were analyzed by western blot. Right: Quantification of the differences in protein levels among control and 2.5 μM C816, 
C830 and C800 treated cells.* Significant differences respect to controls (p <0.05).
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To quantify the effect of each compound on tight 
junctions and focal adhesions proteins levels, western 
blot analysis of claudin-2 (CLDN2), OCLN and vinculin 
(VCL) were performed. C816 treatments were again 
included for comparison purposes and as positive controls. 
Results supported those previously obtained by confocal 
microscopy confirming that C816 and C830 are capable 
of decreasing CLDN2 and increasing OCLN cytoplasmic 
levels (Figure 2B). OCLN localized at tight junctions was 
lost after centrifugation as just the soluble protein fraction 
was recovered for western blot. Finally, no significant 
variations in tubulin-β (TUBB) levels were detected and 
just C816 treatments significantly decreased VCL (2B).
Crambescidins affect CDKs and cyclins 
transcriptional regulation leading to G1 cell 
cycle arrest
Considering their capacity to inhibit tumor cell 
growth, C830 and C800 effect on cell cycle progression 
was evaluated. Results showed that after 24 h, 1 μM and 
2.5 μM C830 caused an accumulation of HepG2 cells in 
the GO/G1 phase. At this time-point no restriction was 
produced by C800 (Figure 3A, 3B). Analysis of cell cycle 
regulators expression showed that C830 down-regulated 
cyclins A and D (CCND2 and CCNA2), and cyclin-
dependent kinases 2, 6 and 1 (CDK2, CDK6 and 1). On 
the contrary, this compound up-regulated cyclin-dependent 
kinase inhibitors 1 and 2 (CDKN2A, CDKN2D and 
CDKN1A) (Figure 3C). In the case of C800, no variations 
were detected after 24 h (Figure 3C). In fact, cell cycle 
inhibition produced by C800 was just observed after 48 h 
of treatment (Figure 3D, 3E).
Crambescidins induce mitochondrial-mediated 
apoptosis of HepG2 cells
C830 and C800 ability to activate programmed cell 
death following cell cycle arrest was assayed by different 
methods. Flow cytometric and confocal microscopy 
analysis using Annexin V and IP showed that C830 induces 
cellular apoptosis after 24 h. C800 also increased the 
apoptotic population but after 48 h (Figure 4A, 4B, 4C). 
Phosphatidylserine translocation caused by C816 was higher 
than that produced by C830 and C800 (Figure 4A, 4B, 4C). 
Mitochondrial function and integrity were also analyzed 
since these organelles play a major role in mediating the 
majority of apoptotic pathways in mammalian cells [18, 
19]. After 24 h, C816 and C830 disrupted mitochondrial 
integrity with a dose-dependent effect (Figure 5A, 5B, 
5C). Mitochondrial integrity alterations caused by 2.5 μM 
C800 were also observed after 48 h treatments (Figure 5A, 
5B, 5C). Since apoptosis is primarily mediated through 
activation of specific intracellular cysteine proteases known 
as caspases [20], activity of the central apoptotic effector 
enzyme caspase-3 was measured. Fluorometric analyses 
revealed a significant increment in caspase-3 activity caused 
by C830 within 24 h. C800 also increased capase-3 activity 
but after 48 h treatments (Figure 6A).
Crambescidins activate some key downstream 
events of the p-53 pathway
C816 and C830 up-regulated several downstream 
targets of the p53 transcription factor that mediate different 
biological outcomes (Figure 6B, 6C). Both, C830 and 
C816, increased the expression of IGF-BP3 and PUMA 
(BBC3) genes, both directly activated by p53 as part of 
the program to bring about apoptosis (Figure 6C). These 
compounds also induced the expression of several genes of 
the p53 network implicated in promoting cell cycle arrest 
(Figure 6D). These changes were also observed at the 
protein level as determined by the increase of CDKN1A 
and PUMA and the decrease CDK2 and cyclin D detected 
by Western Blot analysis (Figure 6E).
Crambescidins can induce apoptotic cell death 
via p-53-independent mechanisms
To elucidate if crambescidins could induce cell 
cycle arrest and apoptotic death of tumor cells in a p53-
independent manner, casapase-3 activity determination 
following p53 inhibition with Pifithrin α in p53 expressing 
cells, and effects on the p53-null PC3 prostate cancer 
cells viability were also assayed. Statistically significant 
decreases of caspase-3 activity between functional and 
p-53 inhibited cells were detected for the three PGAS 
tested (Figure 7A). Even this, p53 inhibition could not 
completely abolish apoptosis induced by crambescidins. 
Similarly, low concentrations of C830 reduced PC3 
cells growth by approximately 30% after 48 h while no 
significant induction of cell death was caused by the same 
concentrations of C800 (Figure 7B).
Crambescidin 816 impairs growth of colon 
carcinoma xenograft models
Three doses of C816 (0.5, 1 μM, and 2 μM) were 
selected to assay the in vivo antitumor activity of C816 
based on toxicity assays results. Experiments were carried 
out at 35°C to favor tumor cell growth. In addition, 
embryo survival rates were annotated at the end of the 
experiments, being the obtained percentages 53.23 % (33 
out of 62) for negative controls, 28.17 % (20 out of 71) for 
injected embryos without treatment, 38.64 % (17 out of 
44) for 0.5 μM C816, 42.50 % (17 out of 40) for 1.0 μM 
C816, 52.00 % (13 out of 25) for 2.0 μM C816 and 50.00 
% (20 out of 40) for 500 μM 5-FU.
The tumor growth in embryos treated with 
C816, 5-FU and untreated controls was observed after 
completion of treatments. Embryos treated with 0.5 μM 
C816 showed a slight tumor regression while, 1 and 2 
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Figure 3: Crambescidins arrest cell cycle progression in the G0/G1 phase. A. Representative histograms of the cell cycle 
obtained after flow cytometry analysis of 2.5 μM C816, C830 and C800-treated HepG2 cells for 24 h. B. Quantification of the cell 
population percentages in each phase of the cell cycle in control and HepG2 cells treated with 2.5 μM C816, C830, C800 and 1 μM C830 
and C800 for 24 h (p <0.05, n =2). C. Down-regulation of CDK1, CDK2, CCND2 and CCNA2 mRNA and up-regulation of CDKN2A 
and CDKN2D mRNA in 2.5 μM C816, C830 and C800-treated cells after 24 h as determined by qRT-PCR. D. Quantification of the cell 
population percentages in each phase of the cell cycle in control and HepG2 cells treated with 0.5, 1 and 2.5 μM C800 for 48 h (p <0.05, n 
=2). E. Representative histograms of the cell cycle obtained after flow cytometry analysis of 0.5, 1 and 2.5 μM C800-treated cells for 48 h.
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Figure 4: Crambescidins induce intrinsic apoptotic death of tumor cells. A. Annexin V and PI staining of HepG2 cells after 0.5, 
1 and 2.5 μM C816, C830 and C800 treatments for 24 and 48 h analyzed by confocal microscopy. B. Annexin V apoptosis determination 
of HepG2 cells treated with 1 μM C816, 2.5 μM C830 and 2.5 μM C800 for 24 h and 2.5 μM C800 for 48 h. Representative plots. C. 
Quantification of the different subpopulations as determined by flow cytometry.
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Figure 5: Crambescidins’ effect on mitochondrial function. A. Effects of 0.5, 1 and 2.5 μM C816, C830 and 0.5, 1 and 2.5 μM 
C800 treatments on mitochondrial membrane potential after 24 and 48 h, respectively as determined using MitoTracker® Red CM-H2XRos 
staining (p<0.05). B. Representative overlay histograms of mitochondrial viability of control (red line), 0.5 (green line), 1 (blue line) and 
2.5 μM (black line) treated cells as determined by flow cytometry using Mito Tracker® Deep Red-FM. C. Population percentages of HepG2 
cells (mean ± SEM) in the R regions (for R1, 2, 3 and 4 regions determination see Supplementary Figure S1) after 24 h treatments with 
C816, C830 and 48 h with C800 (p <0.05).
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Figure 6: Death signaling and effector pathways activated by crambescidins. A. Caspase-3 activity in HepG2 cells treated 
with C816 and C830 for 24 h and with C800 for 48 h. *Significant differences with respect to controls (p <0.05, n = 3). B. Up-regulation 
of BBC3, CDKN1A, GADD45, IGFBP3 and 14-3-3σ genes mRNA in C816-treated cells for 24 h as determined by qRT-PCR. C. Up-
regulation of BBC3, CDKN1A, GADD45, IGFBP3 and 14-3-3σ genes mRNA in 2.5 μM C816 and C830-treated cells for 24 h as determined 
by qRT-PCR. D. Schematic illustration of the molecular downstream targets of the cellular response elicited by crambescidins that mediate 
their different biological outcomes. E. Western blot analysis of proteins involved in crambescidin-mediated cell cycle arrest (p21, Cdk2 and 
cyclin D) and apoptosis (PUMA) induction. * Significant differences respect to controls (p <0.05).
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μM C816 caused a significant decrease of tumor growth 
compared to untreated controls (p < 0.05) (Figure 8A, 8B, 
8C). Administration of 500 μM 5-FU also reduced tumor 
growth but without reaching the effect produced by C816 
(Figure 8A, 8B, 8C). Although not significant, a slight 
increase in C816-treated embryos survival rates was also 
detected (Figure 8D).
DISCUSSION AND CONCLUSIONS
We have previously reported C816 ability to reduce 
viability of a wide range of human tumor-derived cell 
lines also inhibiting cell migration and adhesion [11]. 
Herein, we further investigated the molecular mechanisms 
underlying these bioactivities and focused on other 
members of the crambescidin family of compounds.
Results showed that either C830 or C800 reduce 
tumor cells viability mainly after 48h exposure to low 
concentrations of these molecules (0.5 μM and 1 μM). 
However, the inhibition percentages were always lower 
than that produced by the same concentrations of C816. 
The IC50 values of the three compounds supported these 
results confirming that C816 reduces tumor cells survival 
with a higher potency than C830 and C800.
In the present study we also show that crambescidins 
decreased cell-cell and cell-matrix adhesions. While 
disruption of tight junctions and focal adhesions appears 
early after 6 h exposure to low concentrations of C816 
and progress up to 24 h, in the case of C830 higher 
concentrations (2.5 μM) and longer treatments (24 h) 
were necessary to produce similar effects. Alterations 
produced by 2.5 μM C800 were less noticeable and just 
comparable with those produced by 0.5 μM C816 after 
6 h [11]. Accordingly, immunocytochemistry and western 
blot analysis showed that crambescidins decrease the 
concentrations of two major integral proteins (OCLN 
and CLDN2) in the plasma membrane disrupting tight 
junctions by inducing OCLN cytoplasmic translocation 
and reducing CLDN2 protein expression. Furthermore, 
C816 and C830 disrupt cell attachment to extracellular 
matrix through the reduction of VCL in focal adhesions. 
Both compounds also induce tubulin depolymerization 
Figure 7: p-53 implication in crambescidin-induced apoptosis. A. Caspase-3 activity determination for C816, C830 and C800-
treated cells after p-53 inhibition. *Significant differences with respect to controls and between treatments groups (p <0.01). B. Viability 
of p53-null PC3 cells after C830 and C800 treatments during 24 and 48 h as determined by the MTT method. *Significant difference with 
respect to controls (p <0.01).
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Figure 8: Crambescidin 816 induces tumor regression in an in vivo colorectal carcinoma model. A. In vivo anticancer 
activity of C816 in a human tumor xenograft model. Representative Z-projection images of the tumor development in control and treated 
embryos after 48 h. B. Three-dimensional reconstruction of tumor development in control and treated embryos after 48 h. C. Tumor 
fluorescence intensities (mean ± SEM) and percentages of decrease in tumor volumes of treated embryos after 48 h. D. Survival rates of 
control and treated embryos (median and Q1, Q3). *Significant difference with respect to controls (p <0.05).
Oncotarget83082www.impactjournals.com/oncotarget
and stress fibers disassembly compromising cytoskeletal 
integrity and dynamics. A direct effect of crambescidins 
on tubulin polymerization was also observed. Both C816 
and C830 partially inhibited tubulin polymerization while 
C800 only produced a temporal delay reaching control 
levels after 1 h. Alterations of the tubulin cytoskeleton 
were not observed after 24 h treatments with 2.5 μM 
C800 indicating that, for this compound, cytoskeletal 
rearrangements might be later events following cell 
detachment [21, 22].
Crambescidins inhibited the cell cycle 
progression in the G0/G1 phase with different potencies 
(C816>C830>C800). In direct relation with this 
observation, the assayed compounds down-regulated 
CCND2, CCNA2, CDK2, CDK6 and CDK1, as well as 
up-regulated CDKN2A, CDKN2D and CDKN1A. These 
changes ultimately resulted in the observed G0/G1 cell 
cycle blockage since CDK2 associated with cyclins A, 
D and E, and also cyclin D in association with CDK4 
or CDK6, control the G1 to S phase transition [23, 24]. 
Similarly, CDKN2A, CDKN2D and CDKN1A cyclin-
dependent kinase inhibitors prevent S-phase entry [25]. 
Crambescidins up-regulated different genes of the p53 
transcriptional program resulting in cell cycle arrest 
and apoptosis. In fact, p-53 ability to promote cell cycle 
arrest is fairly well understood in terms of its ability to 
transactivate CDKN1A, GADD45 and 14-3-3 genes 
[26–29], all of which were induced by C816 and C830 
after 24 h. Other target genes induced by crambescidins 
are known to be downstream mediators of apoptotic 
cell death [30–34]. Thus, C816 and C830 increased the 
expression of IGFBP3 and other p-53 activated genes 
(BAX, NOXA, and PUMA) involved in mitochondrial 
damage with concomitant release of cytochrome c into 
the cytoplasm [35]. These results are in concordance with 
the disruption of the mitochondrial integrity caused by the 
three crambescidins and with the subsequent activation of 
the executor caspase-3 observed.
The influence of the p53 response in deciding tumor 
cell fate after crambescidin exposure was also confirmed. 
Caspase-3 activity was significantly decreased following 
p-53 inhibition and exposure to the three PGAS tested 
without reaching control level. Furthermore, PC3 cells 
underwent cell death in response to C830 and C816. 
Both results indicate that, while the p-53 network can 
contribute to programmed cell death induction, it is not 
the unique route involved in its signaling. We further 
studied the role of p-53 in crambescidins-induced cell 
death and demonstrated that these compounds increase 
the transcriptional expression of several components of the 
p-53 pathway and their respective proteins. Inhibition of 
p-53 ameliorated but did not abolish crambescidin-induced 
cell death demonstrating that this tumor suppressor 
contributes but it is not essential for their effects.
Treatments with low concentrations of C816 induced 
cell detachment from the ECM within the first 6 hours 
of exposure in the absence of caspase activation [11]. A 
similar delay was also observed when cells were treated 
with high concentrations of C800 for 24 h. The existing 
interdependences between matrix adhesions, cytoskeleton 
and signaling pathways regulating cell proliferation and 
death indicate that transmembrane crosstalks interruption 
can restrict cell cycle progression through G1 into 
S phase and lead to anoikis through mitochondrial 
apoptotic pathways [21, 36–41]. Although in the case of 
crambescidins obtained results provide strong evidences 
supporting this possibility, further research is still needed 
in order to confirm this.
Taken together, these results highlight the existing 
differences between C816, C830 and C800 in terms of 
potency, but also support the similarity regarding to their 
bioactivities and mechanisms of action. The presence of a 
hydroxyl group at C-13 induces higher biological effects. 
The hemiaminal group at C-13 is highly reactive and can 
lead to an iminium after an easy dehydration process. 
These iminiums are known to be highly electrophilic 
towards all types of nucleophiles and could explain the 
higher potency of C816.
Xenograft assays demonstrated that C816 impairs 
the growth of colorectal carcinoma (CRC) HTC-116 
cells in vivo. This cell line harbors one of the most 
common mutations in CRC, a K-RAS glycine-to aspartate 
mutation at codon 13 (Gly13Asp), accounting to ~20% 
of K-RAS mutations [42]. Metastatic CRC response to 
anti-epidermal growth factor receptor antibody therapies 
inversely correlates with oncogenic activation of the RAS/
RAF signaling pathway [43]. Therefore, C816 ability to 
reduce survival of cancer cells carrying constitutively 
active RAS and WT K-RAS (HT29) is also interesting in 
terms of its possible therapeutic implications. The higher 
potency of C816 compared to 5-FU against K-RAS mutant 
cells was also remarkable since 5-FU is commonly used as 
a standard first or second-line therapy for metastatic CRC.
In conclusion, these results support the interest of 
crambescidins not just as possible lead drug candidates 
but also as useful therapeutic tools for the study of cell 
adhesion remodeling considering the importance of this 
process as a crucial step in a series of changes that a tumor 
cell undergoes during malignant transformation.
MATERIALS AND METHODS
Reagents and solutions
Eagle’s Minimal Essential Medium (E-MEM) 
and Roswell Park Memorial Institute Medium (RPMI) 
were purchased from Gibco (Thermo Fisher Scientific 
Corporation, Madrid, Spain). Fetal bovine serum (FBS) 
was from Cambrex Corporation (Charles City, USA). 
Penicillin, streptomycin, 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide (MTT), anti-β-tubulin, 
anti-rabbit and anti-mouse IgG horseradish peroxidase-
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linked species-specific whole antibodies, CY3-conjugated 
anti-mouse secondary antibody, Hoechst 33258 and 
propidium iodide were purchased from Sigma-Aldrich 
(Madrid, Spain). Aurum™ Total RNA Mini Kit, Precision 
Plus Protein™ Standards Kaleidoscope™ and iTaq™ 
Universal SYBR® Green Supermix were obtained from 
Bio-Rad Laboratories (Barcelona, Spain). Polyvinylidene 
fluoride (PVDF) membranes, anti-actin and anti-vinculin 
antibodies were purchased from Merck-Millipore 
(Temecula, USA). Anti-claudin 2 antibody was from 
Santa Cruz Biotechnology (Dallas, USA). Anti-occludin, 
anti-occludin Alexa Fluor® 488 conjugate antibodies and 
Oregon Green® 514 Phalloidin were from Molecular 
Probes® (Thermo Fisher Scientific Corporation, Madrid, 
Spain). Anti-p21 and anti-PUMA antibodies were 
purchased from Cell Signaling while anti-CDK2 and 
anti-CyclinD antibodies were obtained from Santa Cruz 
biotechnologies. SuperSignal® West Pico, SuperSignal® 
West Femto, alamarBlue® dye, oligo-dT, RevertAid™ 
M-MuLV reverse transcriptase and EnzChek® Caspase-3 
Assay kit were obtained from Thermo Fisher Scientific 
Corporation (Madrid, Spain). Primers were purchased 
from Integrated DNA Technologies (Iowa, USA) and 
sequences are available from the authors upon request.
Crambescidins isolation
Crambescidin 816, crambescidin 830 and 
crambescidin 800 were purified from C. crambe 
sponges following a previously described protocol [44]. 
Compounds were then identified by both UPLC-HRMS 
and NMR analysis (95% purity) and dissolved in DMSO. 
Treated cells were always exposed to a final DMSO 
concentration lower than 0.2%.
Cell culture
HepG2 cell line was purchased from the American 
Type Culture Collection (ATCC) and cultured in E-MEM 
supplemented with 10% fetal bovine serum, 100 UI/ml 
penicillin and 0,1 mg/ml streptomycin. SK-MEL, OU-31, 
PC-3, OVCAR, MCF-7, HT-29 and HOP-92 cell lines 
were obtained from the US National Cancer Institute 
(NCI) and cultured in RPMI medium supplemented with 
10% fetal bovine serum, 50 UI/ml penicillin and 0.05 mg/
ml streptomycin. All cell lines were maintained at 37°C in 
a humidified 5% CO2 atmosphere.
Cell viability assays
Cell viability was determined using the MTT 
method. Briefly, SK-MEL, OU-31, PC-3, OVCAR, MCF-
7, HT-29 and HOP-92 cells were seeded in 96-well plates 
at a density of 8000 cells per well and treated with 0.5 
μM C830 and C800 for 24 h. MTT was added to culture 
medium four hours before incubations ended. Finally, 
reduced MTT was dissolved in DMSO and absorbance 
was determined at 570 and 670 nm (reference) using a 
Bio-Tek Synergy plate reader (Bio-Tek). For each cell line 
three experiments with n = 8 were performed.
IC50 determination
HepG2 cells were seeded in 96 well plates at a 
density of 8000 cells/well and exposed to 0.1 μM, 0.3 
μM, 1 μM, 2.5 μM, 5 μM, 10 μM and 15 μM C816, C830 
and C800 for 48 and 72h. Cell viability was determined 
using the alamarBlue® dye following manufacturer's 
instructions. Fluorescence values were monitored 
every two hours at 530 excitation and 590 nm emission 
wavelengths. IC50 determinations were achieved via 
nonlinear regression analysis of the obtained results using 
the GraphPad® software. Three experiments with n = 8 
were performed.
Cell cycle analysis
HepG2 cells were treated with 0.5, 1 and 2.5 μM 
C830 for 24 h and with the same concentrations of C800 
for 24 and 48 h. After detachment cells from either 
control or treated cultures were washed twice in PBS 
supplemented with 0.1% BSA and 0.3 mM EDTA and 
fixed in cold 70% ethanol at 4°C for 30 min. Fixed cells 
were washed twice with PBS before final pellet collection 
and nuclei staining for 1 h in 50 μL of Telford reagent 
(75 μM IP, 0.1 mM EDTA, 1.34 mg RNase, 0.1% Triton 
X-100) at room temperature protected from the light.
Samples were processed using a FACSCalibur™ 
cytometer (Becton Dickinson) and post-acquisition 
analysis was carried out using the Summit software 
(DAKO). Each condition was tested in triplicate and 
for every replicate a total number of 10 000 events were 
acquired. Two experiments were performed.
Cell adhesion and cytoskeletal integrity 
assessment by confocal microscopy
HepG2 cells were cultured on poly-lysine coated 
cover slips and treated with 2.5 μM C830, C800 and C816 
for 24 h. Cells were fixed with 4% paraformaldehyde for 
15 min at 4°C and permeabilized with a solution of 0.2% 
Triton X-100 in PBS or fixed with 100% methanol for 5 
min at -20°C depending on the type of staining. Before 
labeling, three washes with PBS-0.1% Tween® 20 were 
made. Cover slips were then incubated with 1:300 anti-
occludin (OCLN), anti-vinculin (VCL) and anti-β-tubulin 
(TUBB) antibodies dissolved in a solution of 2% BSA 
in PBS for 2 h at room temperature. After washing, cells 
were incubated again with 1:500 CY3-conjugated anti-
mouse secondary antibody for 1 h protected from light. 
For occludin staining an antibody conjugated with Alexa 
Fluor® 488 was used avoiding this last step. To visualize 
F-actin phalloidin conjugated with Oregon Green®514 was 
used. Before mounting, cover slips were rinsed with PBS-
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0.1% Tween® 20 and 1 μM Hoechst 33258 was added for 
nuclei counterstaining.
Images were acquired with a NIKON TE2000-
3 confocal microscope. Representative images of each 
condition are presented in this work.
Tubulin polymerization assay
The effect of crambescidins on tubulin 
polymerization was assayed using the fluorescence 
based Tubulin Polymerization Assay Kit (Cytosqueleton) 
following the manufacturer’s instructions. Briefly, a mix 
of tubulin buffer, 1 mM GTP and 1.9 mg/ml tubulin 
was added to a 96 well plate previously loaded with the 
compounds. Tubulin polymerization was immediately 
monitored for 1 h with excitation and emission 
wavelengths set at 350 and 430 nm, respectively using a 
Bio-Tek Synergy plate reader thermostated at 37°C.
Western blot analysis
Control and treated cells were re-suspended in 
RIPA lysis buffer (150 mM NaCl, 1% Triton X-100, 0.5% 
sodium deoxycholate, 0.1% SDS and 50 mM Tris, pH 
= 8) and kept on ice for 30 minutes. Lysates were then 
centrifuged at 14000 RPM, 4°C for 15 min and pellets 
were discarded. Total protein concentrations of samples 
were quantified using a Direct Detect™ spectrometer 
(Merk-Millipore) and equivalent protein amounts 
were resolved by SDS-PAGE and transferred to PVDF 
membranes.
PVDF membranes were blocked overnight at 4°C 
in a solution of 3% non-fat milk and then incubated 
with anti-OCLN 1:3000, anti-VCL 1:5000, anti-
claudin 2 (CLDN2), anti-glyceraldehyde-3-phosphate 
dehydrogenase (GADPH) 2:1000, anti-CDK2 1:1000, 
anti-cyclin D 1:1000, anti-p21 1:1000 and anti-PUMA 
1:1000 antibodies for 3 h at room temperature. After 
washing (3 X with PBS-0.1% Tween® 20) membranes 
were incubated with secondary anti-rabbit and anti-mouse 
IgG horseradish peroxidase-linked antibodies 1:5000 (1 
h, room temperature). Finally, membranes were washed 
and revealed with SuperSignal® West Pico or SuperSignal® 
West Femto using a Diversity detector (Syngene). 
Protein quantification was normalized with GADPH and 
differences between treatments were determined with the 
image analysis software GeneTools (Syngene).
Annexin V and propidium iodide staining and 
analysis
Cells were cultured on poly-lysine coated cover 
slips at a density of 400 000 cells/well and on 6 well plates 
until 70-80 % confluency. Cultures were then treated 
with C830, C800 and C816. After treatment cells were 
stained with Anexin V and IP using the Annexin V-FITC. 
Apoptosis Detection Kit (Immunostep) following the 
manufacturer’s instructions. Stained cells were analyzed 
with a NIKON-TE2000-3 confocal microscope and by 
flow cytometry with an ImageStream II cytometer (Amnis) 
(Supplementary Figure S2A). Each condition was tested in 
duplicate and three experiments were done. Representative 
images of each condition are presented in this work.
Mitochondrial functionality and integrity 
determination
MitoTracker Red CM-H2XRos and MitoTracker® 
Deep Reed FM were used to assess mitochondria function 
and integrity. Briefly, in both cases cells were treated 
with 0.5, 1 and 2.5 μM C816 and C830 for 24h and 
with the same concentrations of C800 for 48 h. Culture 
medium was then removed and a prewarmed (37°C) 
solution containing 200 nM MitoTracker® probe was 
added for mitochondria staining. Cells were incubated 
for 30 min at 37°C protected from the light. MitoTracker® 
Red CM-H2XRos emission was measured using a Bio-
Tek Synergy plate reader (exc 579 nm- em 599 nm) 
while MitoTracker® Deep Reed FM-stained cells were 
mechanically removed by scraping, rinsed twice with fresh 
pre-warmed media and fixed with 4% paraformaldehyde 
(PFA) for 20 min at 4°C. Supernatants were finally 
discarded and pellets resuspended in PBS prior to analysis 
using a FACSCalibur™ cytometer. A total number of 
10 000 events were acquired for each condition. Three 
experiments were performed.
Real-time PCR
Cells were treated with 0.5, 1 and 2.5 μM C816, 
C830 and C800 for 24 h. Total RNA was obtained 
using the Aurum™ Total RNA Mini Kit following 
the manufacturer’s instructions. RNA concentration 
and purity were determined using a Nanodrop™ 2000 
spectophotometer (Thermo Fisher Scientific) and cDNA 
was synthesized using an oligo-dT and a RevertAid™ 
M-MuLV reverse transcriptase following the instructions 
provided by the manufacturer. Real-time PCR was 
performed using iTaq™ Universal SYBR® Green 
Supermix in a StepOne™ real-time PCR system (Applied 
Biosystems) and data were analyzed with the StepOne™ 
Software (Applied Biosystems). Peptidylprolyl isomerase 
A gene (PPIA) was used as an internal normalization 
control and relative quantification between samples was 
performed using the ΔΔCt method. Each experimental 
condition was analyzed in triplicate.
Caspase-3 activity
Control, 0.5, 1 and 2.5 μM C816, C830 and 
C800 treated cells, alone or in combination with 50 μM 
Pifithrin α, were harvested and rinsed twice with PBS 
before cellular lysis. Caspase-3 activity was determined 
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using the EnzChek® Caspase-3 Assay kit following the 
manufacturer’s instructions.
Zebrafish toxicity assessment and tumor 
xenograft assay
Adult zebrafish (WT) were fed and kept together at 
28.5°C with a light/dark cycle of 14/10 h following The 
Zebrafish Book recommendations [45]. Embryos were 
obtained as massive spawning (non directed crossing) 
inside the aquarium for both, toxicity and xenograft 
assays, and were maintained in sterile dechlorinated tap 
water (SDTW).
The maximum non-toxic dose of C816 on zebrafish 
embryos was initially established by a toxicity assay 
conducted at 35°C in 96 well-plates for 96 h. Three 
different doses of C816, dissolved in 0,1 % DMSO, were 
evaluated on 48 hpf (hours post fecundation) embryos (10, 
5 and 1 μM; n=8 per concentration). SDTW was included 
as negative control (n=24) and 3,4-dichloroaniline (DCA: 
20, 10 and 4 mg/L; n=8 per concentration) was selected as 
positive control to check the sensitivity of the fish strain 
used following the recommendations for the zebrafish 
embryo toxicity test (OECD Test No. 236). All individuals 
exposed to 10 and 20 mg/L DCA died, and just 12.50% 
of those exposed to 4 mg/L survived but with important 
morphological alterations, corroborating the sensibility of 
the performed assay.
The zebrafish xenograft model was established by 
transplantation of stable fluorescent colorectal carcinoma 
cells expressing GFP protein (HCT-116-GFP) into 48 
hpf zebrafish embryos. After manipulation animals were 
maintained in 96 well-plates at 35°C for 1 day to favor 
tumor cell proliferation and embryo recovering.
Experiments were carried out using a total number of 
62 negative controls (non-injected) and 71 microinjected 
non-treated embryos, both maintained in SDTW. Different 
doses of C816 (0.5 μM, 1 μM, and 2 μM) were tested in 
44, 40 and 25 individuals, respectively for 48 h. Another 
40 embryos were also exposed to 500 μM 5’-fluoracile (5-
FU) for the same period of time (48 h).
Six experiments were performed and both, tumor 
volumes and embryo survival rates, were annotated.
Computerized image analysis
Tumor volumes were individually recorded for each 
embryo by image acquisition with a NIKON TE2000-3 
confocal microscope set for GFP detection (Z-stacks of 
X-Y image planes) before and after treatment. Obtained 
images were then processed with the Image J software by 
collapsing the data from 3D into 2D using a z-projection 
(sum projection) prior to tumor integrated intensity 
determination. The ratios of pre-treatment fluorescence 
intensity to post-treatment tumor intensity were finally 
calculated for each individual to determine tumor size 
variations. The percentage of tumor regression was 
calculated as the percentage ratio of the difference between 
baseline fluorescence intensity and final fluorescence to 
the baseline intensity.
Following all experiments, zebrafish embryos were 
euthanized by an overdose of tricaine. Care, use and 
treatment of zebrafish were done under approval of the 
Santiago de Compostela University Bioethics Committee 
in compliance with Principles of Laboratory Animal Care 
of national laws.
Statistics
The results were analyzed using the SIGMAPLOT® 
software. For in vitro experiments One-way ANOVA 
was used to test for differences among groups and the 
Holm-Sidak multiple-range test was used for multiple 
comparisons between groups. Tumor development 
statistical analyses were calculated by the Mann-Whitney 
Rank Sum test. Significance was accepted at p < 0.05 in 
all cases.
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